Two Sigma Investments, LP Xeris Biopharma Holdings, Inc. Transaction History

Two Sigma Investments, LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$1.7 - $2.45 $175,203 - $252,499	-103,061 Reduced 79.36%	26,803 $60,000
Q1 2024 May 15, 2024	BUY	$2.04 - $3.22 $66,330 - $104,698	32,515 Added 33.4%	129,864 $286,000
Q4 2023 Feb 14, 2024	SELL	$1.47 - $2.36 $18,488 - $29,681	-12,577 Reduced 11.44%	97,349 $228,000
Q3 2023 Nov 14, 2023	SELL	$1.8 - $2.69 $166,114 - $248,249	-92,286 Reduced 45.64%	109,926 $204,000
Q2 2023 Aug 14, 2023	BUY	$1.82 - $2.98 $368,025 - $602,591	202,212 New	202,212 $529,000
Q2 2022 Aug 15, 2022	SELL	$1.48 - $2.64 $222,161 - $396,287	-150,109 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$2.0 - $2.87 $300,218 - $430,812	150,109 New	150,109 $384,000

143

60M

148K

45.7K

Ticker XERS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 135,956,992
Market Cap $462M
Description
Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, h...

Get notified when there are updates to the investment portfolio of Two Sigma Investments, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Investments, LP with notifications on news.